The ERBB network facilitates KRAS-driven lung tumorigenesis

KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling, however recent data suggest...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Transl Med
Main Authors: Kruspig, Björn, Monteverde, Tiziana, Neidler, Sarah, Hock, Andreas, Kerr, Emma, Nixon, Colin, Clark, William, Hedley, Ann, Laing, Sarah, Coffelt, Seth B., Quesne, John Le, Dick, Craig, Vousden, Karen, Martins, Carla P., Murphy, Daniel J.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6881183/
https://ncbi.nlm.nih.gov/pubmed/29925636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aao2565
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki